| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/EAT.22059 |
| P8608 | Fatcat ID | release_vnwzgjvua5etjhotfqxe3433wu |
| P698 | PubMed publication ID | 23001863 |
| P5875 | ResearchGate publication ID | 264667405 |
| P50 | author | Jocelyn Lebow | Q84184708 |
| Patricia Erwin | Q107973218 | ||
| Mohammad Murad | Q37831481 | ||
| P2093 | author name string | Leslie A Sim | |
| P2860 | cites work | Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? | Q47294699 |
| Factors associated with the increase in resting energy expenditure during refeeding in malnourished anorexia nervosa patients. | Q50984656 | ||
| Olanzapine therapy in anorexia nervosa: psychobiological effects. | Q51903375 | ||
| Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis | Q55969864 | ||
| Olanzapine versus placebo for out-patients with anorexia nervosa | Q83680716 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Interaction revisited: the difference between two estimates | Q29619619 | ||
| Incidence, prevalence and mortality of anorexia nervosa and other eating disorders | Q34567779 | ||
| QT alterations in psychopharmacology: proven candidates and suspects | Q34617497 | ||
| The outcome of anorexia nervosa in the 20th century | Q34770024 | ||
| A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study | Q35209098 | ||
| Side effects of atypical antipsychotic drugs | Q35849629 | ||
| Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. | Q35956610 | ||
| Neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems | Q36106396 | ||
| The role of olanzapine in the treatment of anorexia nervosa | Q36693209 | ||
| What potential role is there for medication treatment in anorexia nervosa? | Q37236316 | ||
| Atypical antipsychotics and anorexia nervosa: a review | Q37669911 | ||
| Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study | Q43071698 | ||
| Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia | Q43491943 | ||
| A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. | Q43667670 | ||
| Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial | Q43877058 | ||
| Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial | Q46536439 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| meta-analysis | Q815382 | ||
| anorexia nervosa | Q131749 | ||
| P304 | page(s) | 332-339 | |
| P577 | publication date | 2012-09-24 | |
| P1433 | published in | International Journal of Eating Disorders | Q15752483 |
| P1476 | title | The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis | |
| P478 | volume | 46 |
| Q91635806 | A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa |
| Q47625633 | Advances in the treatment of anorexia nervosa: a review of established and emerging interventions |
| Q60633749 | Anorexia nervosa |
| Q38202549 | Anorexia nervosa and bulimia nervosa: brains, bones and breeding |
| Q38619403 | Anorexia nervosa: aetiology, assessment, and treatment |
| Q36256978 | Association of Beck Depression Inventory score and Temperament and Character Inventory-125 in patients with eating disorders and severe malnutrition |
| Q35553293 | Atypical antipsychotics as augmentation therapy in anorexia nervosa |
| Q36915346 | BDNF-Val66Met variant and adolescent stress interact to promote susceptibility to anorexic behavior in mice. |
| Q35215020 | Biological therapies for eating disorders |
| Q38163315 | Clinical problems encountered in the treatment of adolescents with anorexia nervosa |
| Q36292328 | Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients |
| Q35596773 | Could dopamine agonists aid in drug development for anorexia nervosa? |
| Q36118154 | ESCAP Expert Paper: New developments in the diagnosis and treatment of adolescent anorexia nervosa--a European perspective |
| Q34761274 | Eating disorders and psychosis: Seven hypotheses |
| Q50072523 | Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics |
| Q90430285 | Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial |
| Q38125946 | Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: a nine-case chart review |
| Q38255056 | Has the time come for a staging model to map the course of eating disorders from high risk to severe enduring illness? An examination of the evidence |
| Q38347858 | Is enhanced cognitive behavioral therapy an effective intervention in eating disorders? A review |
| Q64105478 | Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews |
| Q34460149 | Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa |
| Q27007030 | Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa |
| Q64332771 | Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics |
| Q38197083 | Pediatric feeding and eating disorders: current state of diagnosis and treatment |
| Q38386296 | Psychopharmacologic treatment of eating disorders: emerging findings |
| Q99412617 | Psychotropic medication use in treatment-seeking youth with eating disorders |
| Q87197278 | Psychotropic medications in adult and adolescent eating disorders: clinical practice versus evidence-based recommendations |
| Q89036582 | Psychotropic usage by patients presenting to an academic eating disorders program |
| Q24187512 | Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa |
| Q38268590 | Weight gain and antipsychotics: a drug safety review |
| Q86997964 | [Hematological changes in adolescent anorexia nervosa] |
Search more.